Will taking everolimus (Afinitor) for 15 days increase the risk of cancer?

Everolimus is an anti-tumor and immunosuppressive drug that targets the mTOR (mammalian target of rapamycin) pathway and is widely used to prevent and treat rejection after certain tumors and organ transplants. In the early stages of taking drugs, such as 15 days, concerns about the risk of cancer are mainly reflected in the effects of drugs on cell proliferation and the immune system. Everolimus itself is not a carcinogen, and its anti-proliferative properties actually have an inhibitory effect on some cancers.

In clinical observations and trials, Everolimus is usually used in patients with breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumors, etc. Its main effect is to inhibit tumor growth and angiogenesis. With short-term use, such as around two weeks, the drug has not yet achieved long-term cumulative effects, and there is no clinical data to show a significant increase in the risk of new cancers during such a short period of administration. Therefore, 15 days of medication usually does not directly cause cancer.

However, it should be noted that Everolimus has a certain immunosuppressive effect, and long-term use may reduce the body's immune surveillance ability against abnormal cells, thereby potentially increasing the risk of infection or malignant tumors. However, this risk mainly occurs under long-term continuous use or high-dose treatment. Compared with short-term, regular dose use, the risk is extremely low. Therefore, for patients who have just taken it for 15 days, the risk of cancer is almost negligible.

Clinically, patients should maintain regular review while takingEverolimus, including blood routine, liver and kidney function monitoring, and necessary imaging examinations. Doctors also evaluate individual risks based on the patient's underlying medical conditions, family history of cancer, and use of other medications. In general, short-term use of Everolimus is relatively safe, and the risk of cancer does not increase significantly within 15 days. However, medical advice should be followed and long-term safety management should be paid attention to.

Reference materials:https://www.drugs.com/